



Version 1.8 doi:10.3762/strenda.18

as approved on  $30^{\text{th}}$  November 2021

The STRENDA Commission (<u>St</u>andards for <u>Reporting Enzymology Da</u>ta) compiled the following Guidelines, as a service to the community, to define the minimum amount of information that should accompany any published enzyme activity data.

The current STRENDA Guidelines (List Level 1A) was reviewed on the STRENDA meeting in November 2021 in terms of consistency of form and content, as well as of the order and plausibility of the list entries. In addition, a few essential parameters for the measurement of equilibrium constants are now included.

#### List Level 1A

defines data that are recommended for the methods section for publishing enzyme data. This information should allow the reproducibility of the results.

| Data                                      | Comments   |
|---|--|
| Identity of the enzyme                    |  |
| Name of reaction catalyst                 | name, preferably the accepted name from the IUBMB<br>Enzyme List   |
| Fully balanced chemical reaction equation | elements and charges balanced. See convention in R.A. Alberty "Thermodynamics of Biochemical Reactions", <u>doi:10.1002/0471332607</u> |
| EC number                                 |  |
| Oligomeric state                          | number of different subunits   |
| Sequence or sequence accession number     |  |
| Organism/species & strain                 | NCBI Taxonomy ID   |
| Additional information on the             |  |
| enzyme                                    |  |
| Isoenzyme                                 | naturally occurring variant or indication of selection of alternative  |
| Tissue                                    |  |
| Organelle                                 |  |
| Localization                              | within cell. Specify what localization is based on   |





| Data   | Comments  |
|--|---|
| Post-translational modification                                      | add only when determined  |
| Preparation  |   |
| Description  | e.g., commercial source, procedure used or reference along with modifications   |
| Artificial modification  | e.g., truncated, His-tagged, fusion protein, lacking native glycosylation   |
| Enzyme or protein purity   | purity defined by which criteria. Specify whether protein or enzyme was purified.   |
|  | e.g., apparently homogeneous by PAGE, crude mitochondrial fraction, determined by MS  |
| Metalloenzyme  | mutant, content, cofactors  |
| torage Conditions  |   |
| Storage temperature  | if frozen, freezing method, <i>e.g.</i> , -20 °C flash  |
| Atmosphere if not air  |   |
| pH   | e.g., 7.0   |
| At which temperature was the pH measured?                            | e.g., 25 °C   |
| pH-Buffer & concentrations (including counter-ion)                   | e.g., 200 mM potassium phosphate, 100 mM HEPES-<br>KOH. If pH is adjusted by addition of acid or base not<br>shown in buffer name, make this clear –<br>e.g., 50 mM sodium acetate adjusted with HCl. |
| Metal salt(s) & concentrations                                       | e.g., 10 mM KCl, 1.0 mM MgSO <sub>4</sub>   |
| Other components   | e.g., 1.0 mM EDTA, 1.0 mM dithiothreitol,<br>10% v/v glycerol, 20% w/w DMSO, 1 mg/ml<br>PEG2000, 2 mg/ml BSA, peptidase inhibitors  |
| Enzyme/protein concentration   | molar concentration if known, (quote assumed molar mass), otherwise mass concentration,   |
|  | e.g., $\mu$ M or mg ml <sup>-1</sup>  |
| Optional:  | e.g., less than 10% loss after 1 month  |
| Statement about observed loss of activity under the above conditions |   |





| Data                                  |              | Comments |  |
|---------------------------------------|--------------|----------|--|
| Statement about the thawing procedure | e.g., on ice |          |  |

| •  |  |
|--|--|
| Identity and purity of all<br>assay components | identified unambiguously, ideally by reference to ID<br>from database (such as PubChem, ChEBI), or using a<br>textual identifier (such as InChI) and/or showing<br>chemical structure (or SMILES).<br>Origin of compounds used with statement on purity. |
| Measured reaction                              | as a stoichiometrically balanced equation  |
|  | e.g., 2 mol substrate oxidized per mol $O_2$ consumed, with all products identified  |
| Assay temperature                              |  |
| Assay pressure                                 | if it is not atmospheric; indicate if not aerobic  |
| Atmosphere if not air                          |  |
| Assay pH                                       | How was it measured?   |
| Buffer & concentrations                        | e.g., 100 mM Tris-HCl, 200 mM potassium phosphate,<br>including counter-ion.<br>If pH is adjusted by addition of acid or base not shown<br>in buffer name, make this clear –<br>e.g., 50 mM sodium acetate adjusted with HCl.                            |
| Metal salt(s) & concentrations                 | e.g., 10 mM KCl, 1.0 mM MgSO <sub>4</sub>  |
| Other assay components                         | e.g., 1.0 mM EDTA, 1.0 mM dithiothreitol   |
| Coupled assay components                       | if relevant  |
| Substrate & concentration ranges               | e.g., 1 - 100 mM glucose, 5 mM ATP   |
| Enzyme/protein concentration                   | Molar concentration if known, otherwise mass concentration.  |
|  | e.g., mg ml <sup>-1</sup> or better: $\mu M$   |
| Varied components                              | e.g., inhibitor concentration  |
| Total assay mixture ionic strength             |  |

### Activity





| Data  | Comments   |
|---|--|
| Initial rates of the reaction measured                                  | determine how established, estimate ranges in<br>substrate/product concentrations at the last data<br>point.   |
|   | e.g., true initial tangent or average over specified time  |
| Proportionality between initial velocity and enzyme concentration       | if available   |
| Enzyme activity   | Ideally $k_{cat}$ (i.e. $V_{max}$ /enzyme concentration), otherwise<br>expressed as amount product formed per amount<br>enzyme protein present per time unit. Activity is<br>sometimes reported as enzyme unit or international<br>unit (1 IU = 1 µmol min <sup>-1</sup> ). The katal (mol/s) may<br>alternatively be used as a unit of activity (conversion<br>factor 1 unit = 16.67 nkat). |
|   | Specify at which (range of) enzyme concentration(s) this was determined.   |
| Equilibrium measurements  |  |
| Evidence that reaction reached equilibrium                              | e.g., approached from both (or all if multiple substrates/products) directions   |
| State which of all reactants were measured directly                     | e.g., glucose phosphate and glucose measured directly, excess phosphate estimated by mass balance  |
| Range of starting material and product concentrations in the experiment | ideally a table of all initial and measured equilibrium concentrations   |
| Complexing metal ions   | if the reaction involved species that might bind these<br>(e.g., phosphate esters), essential to report estimated<br>pMg and/or pCa  |
| Methodology   |  |
| Assay method  | a literature reference may suffice for an established procedure but any modification should be detailed  |
| Type of assay   | e.g., continuous or discontinuous, direct or coupled   |
| Reaction stopping procedure   | in the case of discontinuous assays  |
| Direction of the assay  | with respect to the reaction equation provided   |
|   | e.g., NAD reduction by alcohol dehydrogenase;<br>alcohol + NAD <sup>+</sup> -> aldehyde or ketone + NADH + H <sup>+</sup>  |
| Reactant determined   | e.g., NADH formation, $O_2$ utilization  |





| Data                             | Comments  |
|----------------------------------|---|
| Additional material desirable    |   |
| Free metal cation concentrations | e.g., of $Mg^{2+}$ and $Ca^{2+}$ , specify how calculated |

#### About the STRENDA Commission:

The STRENDA Commission is formed by an international panel of highly-regarded scientists who bring in diverse expertises such as biochemistry, enzyme nomenclature, bioinformatics, systems biology, modelling, mechanistic enzymology and theoretical biology.

The Commission was founded in 2003 and is supported by the Beilstein-Institut since then.

Members of the Commission are: **B.M. Bakker** (University Medical Center Groningen, The Netherlands), **A. Cornish-Bowden** (CNRS-BIP, Marseilles, France), **P. Fitzpatrick** (University of Texas Health Science Center at San Antonio, San Antonio, TX, USA), **P. Halling** (University of Strathclyde, Glasgow, UK), **T.S. Leyh** (The Albert Einstein College of Medicine, Bronx, NY, USA), **A.G. McDonald** (Trinity College Dublin, Ireland), **M. Neumann-Schaal** (Leibniz Institute DSMZ, Braunschweig, Germany), **C. O'Donovan** (EBI, Cambridge, UK), **J. Pleiss** (University of Stuttgart, Germany), **F.M.Raushel** (Texas A&M University, College Station, TX, USA), **J.M. Rohwer** (University of Stellenbosch, South Africa), **S. Schnell** (University of Notre Dame, IN, USA), **N. Swainston** (The University of Liverpool, UK), **M.-D. Tsai** (Academia Sinica, Taipeh, Taiwan), **K. Tipton** (Trinity College, Dublin, Ireland), **H.V. Westerhoff** (Universities of Amsterdam, The Netherlands), **U. Wittig** (Heidelberg Institute of Theoretical Studies, Germany) **R. Wohlgemuth** (Lodz University of Technology, Poland) and **C. Kettner** (co-ordination, Beilstein-Institut, Frankfurt, Germany).

More information: www.beilstein-strenda.org